For adults and children 6+ with moderate to severe plaque psoriasis
WE’RE COMMITTED TO MAKING COSENTYX® (secukinumab) AFFORDABLE AND ACCESSIBLE
84% of eligible patients who used the co-pay* program paid $0 out of pocket for COSENTYX.†
†2024 data on file.
Co-Pay Plus Terms & Conditions
Offer valid only when used with commercial health insurance. Offer is not available where:
the patient has federal or state health plan benefits (eg, Medicare, Medicaid, TRICARE, VA);
the health plan reimburses for the entire cost of the drug;
the health plan provides no coverage for the drug; or
prohibited by law.
The amount of funding available from the Program is subject to an annual limit. Novartis reserves the right to discontinue the availability of co-pay assistance if, at any time, Novartis determines that the patient is subject to a co-pay maximizer program. Co-pay maximizers are programs implemented by health plans in which the amount of the patient’s out-of-pocket cost is increased to reflect the availability of support offered by a manufacturer assistance program. The patient is responsible for all costs once available funding from the Program is exhausted.
The Program is designed exclusively for the benefit of the patient. The amount of available funding may be reduced or eliminated if it is not credited by the patient’s health plan toward the patient’s out-of-pocket obligations (eg, deductibles, annual out-of-pocket maximums). Program funding may also be reduced or eliminated if the patient’s health plan, directly or indirectly, adjusts, reduces, or waives the patient’s health plan benefits based on the availability of, or the patient’s enrollment in, the Program, or otherwise acts in a manner that materially affects these Terms and Conditions.
Only the patient or their legal guardian or caregiver may enroll the patient in the Program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives (individually and collectively “Plan Administrators”), are prohibited from enrolling patients in the Program.
Patients in the Program are responsible for notifying Novartis of any change in their prescription drug health plan coverage that may conflict or otherwise affect compliance with these Terms and Conditions. By accepting Program funding from Novartis on behalf of participating patients, Plan Administrators agree to not take any action that materially affects compliance with these Terms and Conditions.
Patients may not seek reimbursement for the value received from the Program from any other party (eg, health plans, flexible spending or healthcare savings accounts). Patients are responsible for complying with any applicable limitations and requirements of their health plan related to their use of the Program.
Valid only in the United States and Puerto Rico. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts.
The Program is not health insurance, and may not be combined with any third-party rebate, coupon, or offer. Novartis reserves the right to rescind, revoke, or amend the Program at any time without notice.
Covered Until You’re Covered also known as Bridge Program applies to COSENTYX Subcutaneous Injection only. Eligible patients must have private insurance and a valid prescription for COSENTYX, and a prior authorization, predetermination, or medical exception that has been denied. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides COSENTYX for free to eligible patients for up to 2 years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional Limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.
Get up to 2 years of COSENTYX for free if eligible‡
Individual results may vary. Brooke was compensated for her time.
“My insurance wouldn’t pay for COSENTYX. And then Novartis was nice enough to give me a year for free. So it was a relief not to have to worry about the insurance part of it.”
The cost of biologics varies, based on certain factors. First, there’s the type of insurance you have and your prescription coverage. There are also differences in initial dosing, maintenance dosing, and the potential for dose adjustments. Because of all these factors, costs can vary.
The list (or wholesale) price for COSENTYX, as of January 2026 is $8,492.03 a month for either a 150-mg or a 300-mg dose strength self-injection package and $4,489.34 per intravenous infusion.§ The list price may not reflect the price paid by patients; most patients with prescription coverage will pay less.
§A month is defined as once every 4 weeks. Costs may vary depending on your condition, dosage, and how COSENTYX is taken. The price per IV infusion is for a patient weighing 165 lbs. to 310 lbs. Monthly costs and dosing for IV COSENTYX may vary depending on your body weight.
“You guys have been great about answering questions about my insurance and setting up delivery. I've had no problems at all with getting the medication.”
Individual results may vary. Dewey was compensated for his time.
Questions about your insurance coverage?
You can get more answers to insurance coverage questions and find helpful resources here or download the Insurance Coverage Questions brochure.
COSENTYX is available through a direct-to-patient option
COSENTYX is now available directly to patients who choose to pay out of pocket for the full cost of their prescriptions. The price is $3674.44 or $1837.22 per self-injectable dose. That's a savings of at least 55% off the list price.
Novartis Patient Assistance Foundation
The Novartis Patient Assistance Foundation, Inc. (NPAF)* is an independent, 501(c)(3) non-profit entity that provides certain medications at no cost to eligible patients who cannot afford the cost of Novartis medications supported by NPAF.
Patients may be eligible for NPAF support if they:
- Are a resident of the U.S. or its territories.
- Are prescribed a product on the NPAF formulary.
- Meet NPAF income eligibility requirements.
- Are uninsured or are a qualifying patient with government insurance who cannot afford their out-of-pockets costs and, in the case of Medicare patients, do not qualify for Medicare’s Extra Help Program (Low Income Subsidy).
Please visit www.PAP.Novartis.com for more information.
*NPAF does not provide product to individuals having insurance associated with any type of alternative funding program that conditions, restricts, or adjusts coverage based on application to NPAF or to any other free goods program. To receive support through NPAF, applicants must submit all required documentation, including proof of income and evidence of Extra Help denial as deemed necessary. Only the patient or their legal guardian or caregiver may enroll the patient in the program. Health plans, specialty pharmacies, pharmacy benefit managers, and their agents and representatives are prohibited from enrolling patients in the program. Novartis Patient Assistance Foundation, Inc., at its sole and absolute discretion, reserves the right to modify or discontinue the program at any time and to verify the accuracy of enrollment information submitted.